Use of trimebutine maleate for the prophylaxis and treament of inflammatory gastrointestinal tract diseases

Trimebutine maleate at a daily dose of 600 mg, administered twice daily, addresses inflammatory gastrointestinal diseases by modulating cytokine levels, reducing pro-inflammatory markers and increasing anti-inflammatory cytokines, effectively treating IBS and related conditions.

WO2025170482A1 Publication Date: 2025-08-14OBSHCHESTVO S OGRANICHENNOJ OTVETSTVENNOSTYU BINNOFARM GRUPP
0 Cites 0 Cited by

Patent Information

Application Number
PCT/RU2024/000108
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-02-06
Filing Date
2024-03-29
Publication Date
2025-08-14

AI Technical Summary

Technical Problem

Existing treatments for inflammatory gastrointestinal diseases, such as irritable bowel syndrome (IBS), do not effectively address the underlying inflammatory processes and cytokine imbalances, failing to provide comprehensive relief beyond symptom management.

Method used

Trimebutine maleate, administered in a daily dose of 600 mg, preferably twice daily with an 8-12 hour interval, modulates cytokine levels in the gastrointestinal tract by decreasing pro-inflammatory cytokines IL-1, IL-6, TNF-alpha, and Nf-kb while increasing anti-inflammatory cytokine IL-10, thereby exerting a tissue-specific anti-inflammatory action.

Benefits of technology

Trimebutine maleate significantly reduces pro-inflammatory cytokines and enhances anti-inflammatory cytokines, providing a dose-dependent therapeutic effect that effectively targets and mitigates gastrointestinal inflammation.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to pharmaceutics, and more particularly to gastroenterology, and can be used for the prophylaxis or treatment of inflammatory diseases of the gastrointestinal tract. What is described is the use of trimebutine maleate to achieve a maximum change in the level of the proinflammatory cytokines IL-1, IL-6, TNF-α, NF-κB and the anti-inflammatory cytokine IL-10 in the gastrointestinal tract for the prophylaxis or treatment of acute and chronic inflammatory diseases of the gastrointestinal tract.
Need to check novelty before this filing date? Find Prior Art